These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35165216)

  • 1. Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.
    Hawkins C; Kang M; Bhattacharya D; Cloherty G; Kuhns M; Matining R; Thio C; Samaneka W; Chinula L; Mulinda N; Badal-Faesen S; Sugandhavesa P; Lama J; Gaseitsiwe S; Holzmayer V; Anderson M; Murphy R; Peters M
    AIDS; 2022 Jun; 36(7):975-984. PubMed ID: 35165216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus coinfection differentially impacts hepatitis B virus viral markers based on hepatitis Be antigen status in patients with suppressed viremia.
    Lisker-Melman M; King WC; Ghany MG; Chung RT; Hinerman AS; Cloherty GA; Khalili M; Jain MK; Sulkowski M; Sterling RK
    J Viral Hepat; 2023 Aug; 30(8):700-709. PubMed ID: 37278302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
    Li Y; Xie J; Han Y; Wang H; Zhu T; Wang N; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Thio CL; Li T
    J Acquir Immune Defic Syndr; 2016 May; 72(1):39-45. PubMed ID: 26745828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological responses to tenofovir-alafenamide-containing antiretroviral therapy in people living with HIV co-infected with lamivudine-resistant or lamivudine-susceptible hepatitis B virus.
    Huang YS; Sun HY; Chang SY; Chuang YC; Su YC; Liu WC; Hung CC
    Int J Antimicrob Agents; 2022; 60(5-6):106682. PubMed ID: 36279976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
    He Y; Lin W; Li H; Gu F; Zhong H; Lan Y; Li Y; Guo P; Hu F; Cai W; Tang X; Li L
    Chin Med J (Engl); 2023 Nov; 136(22):2686-2693. PubMed ID: 37881959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.
    Dunn D; Price H; Vudriko T; Kityo C; Musoro G; Hakim J; Gilks C; Kaleebu P; Pillay D; Gilson R;
    J Acquir Immune Defic Syndr; 2021 Jan; 86(1):98-103. PubMed ID: 33306565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
    Boyd A; Maylin S; Moh R; Mahjoub N; Gabillard D; Eholié SP; Danel C; Anglaret X; Zoulim F; Girard PM; Delaugerre C; Lacombefor K;
    J Gastroenterol Hepatol; 2016 Mar; 31(3):634-44. PubMed ID: 26313291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
    Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
    J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co-infected Chinese.
    Yang R; Gui X; Ke H; Xiong Y; Gao S
    J Viral Hepat; 2020 Feb; 27(2):127-134. PubMed ID: 31571343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.
    Kang M; Hollabaugh K; Pham V; Koletar SL; Wu K; Smurzynski M; Aberg JA
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):172-80. PubMed ID: 24694927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.
    Gantner P; Cotte L; Allavena C; Bani-Sadr F; Huleux T; Duvivier C; Valantin MA; Jacomet C; Joly V; Chéret A; Pugliese P; Delobel P; Cabié A; Rey D;
    PLoS One; 2019; 14(4):e0215464. PubMed ID: 30998789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and molecular characterization of hepatitis B virus infection in HIV-infected children in Senegal.
    Toyé RM; Lô G; Diop-Ndiaye H; Cissé AM; Ndiaye AJS; Kébé-Fall K; Dramé A; Cohen D; Pujol FH; Mboup S; Boye CS; Chemin I; Laborde-Balen G; Taverne B; Touré-Kane C
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101502. PubMed ID: 32828748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy.
    Begré L; Boyd A; Plissonnier ML; Testoni B; Salazar-Vizcaya L; Suter-Riniker F; Scholtès C; Béguelin C; Rockstroh JK; Günthard HF; Calmy A; Cavassini M; Hirsch HH; Schmid P; Bernasconi E; Levrero M; Wandeler G; Zoulim F; Rauch A;
    J Infect Dis; 2024 Oct; 230(4):e954-e963. PubMed ID: 38626170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
    Childs K; Joshi D; Byrne R; Bruce M; Carey I; Agarwal K; Taylor C
    AIDS; 2013 Jun; 27(9):1443-8. PubMed ID: 23435302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of treatment-naive HIV/HBV co-infected patients attending ART clinic of a tertiary healthcare centre in eastern India.
    Saha D; Pal A; Biswas A; Panigrahi R; Sarkar N; Sarkar J; Pal M; Guha SK; Saha B; Chakrabarti S; Chakravarty R
    PLoS One; 2013; 8(8):e73613. PubMed ID: 24023688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa.
    Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Danel C; Delaugerre C; Zoulim F; Lacombe K;
    Liver Int; 2019 Feb; 39(2):280-289. PubMed ID: 30257068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
    Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
    Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
    Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4
    Li X; Xu L; Lu L; Liu X; Yang Y; Wu Y; Han Y; Li X; Li Y; Song X; Cao W; Li T
    Front Cell Infect Microbiol; 2023; 13():1178788. PubMed ID: 37207191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
    Boyd A; Maylin S; Gozlan J; Delaugerre C; Simon F; Girard PM; Lacombe K
    Liver Int; 2015 Mar; 35(3):795-804. PubMed ID: 24606220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.